HomeAMLX • NASDAQ
Amylyx Pharmaceuticals Inc
add
In the news
Financials
Income Statement
Revenue
Net Income
Revenue
Net income
| (USD) | Dec 2024info | Y/Y change |
|---|---|---|
Revenue | -665.00K | -100.61% |
Operating expense | 53.30M | 2.03% |
Net income | -37.55M | -893.62% |
Net profit margin | 5.65K | 129,395.87% |
Earnings per share | -0.55 | -885.71% |
EBITDA | -40.49M | -1,911.81% |
Effective tax rate | 1.66% | — |
Balance Sheet
Total Assets
Total Liabilities
Total assets
Total liabilities
| (USD) | Dec 2024info | Y/Y change |
|---|---|---|
Cash and short-term investments | 176.50M | -52.47% |
Total assets | 193.63M | -62.58% |
Total liabilities | 28.87M | -65.64% |
Total equity | 164.77M | — |
Shares outstanding | 88.60M | — |
Price to book | 1.61 | — |
Return on assets | -45.75% | — |
Return on capital | -55.61% | — |
Cash Flow
Net Change in Cash
Net change in cash
| (USD) | Dec 2024info | Y/Y change |
|---|---|---|
Net income | -37.55M | -893.62% |
Cash from operations | -59.01M | -535.45% |
Cash from investing | 64.98M | 210.54% |
Cash from financing | 110.00K | -52.17% |
Net change in cash | 5.56M | -84.10% |
Free cash flow | -45.65M | -239.09% |
Previous close
$3.87
Day range
$3.71 - $3.85
Year range
$1.58 - $7.27
Market cap
334.92M USD
Avg Volume
731.81K
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
About
Amylyx Pharmaceuticals, Inc is a biopharmaceutical company headquartered in Cambridge, Massachusetts. Amylyx is best known for AMX0035, an experimental therapy for amyotrophic lateral sclerosis. AMX0035 was approved for medical use in Canada as Albrioza, in June 2022, and in the United States, as Relyvrio, in September 2022. It was withdrawn in April, 2024. Wikipedia
Founded
2013
Website
Employees
123
